Viatris (VTRS) is back in focus after reporting first quarter 2026 results that topped Wall Street revenue and adjusted EPS expectations, reaffirming full year guidance and highlighting strong cardiovascular demand in Greater China.

The earnings beat and reaffirmed 2026 guidance sit against a share price of $16.48, with the stock down 4.5% on the day but recording a 30 day share price return of 18.9% and a 1 year total shareholder return of 95.1%. This suggests momentum has been building even as short term sentiment cools after the results and CFO transition headlines.

If Viatris’s recent move has you thinking about where growth and income might intersect next, it could be worth scanning for other healthcare names harnessing AI in their businesses through the 32 healthcare AI stocks

With Viatris trading at $16.48 and sitting only modestly below an average analyst target of $17.50 despite a very large estimated gap between price and intrinsic value, investors may ask whether there is still an attractive entry point available or whether the market price already reflects expectations for future growth.

Most Popular Narrative: 58% Undervalued

According to a widely followed narrative on Viatris, a fair value of $39.24 versus the last close at $16.48 points to a very large valuation gap that hinges on a multi year transformation story.

Today, Viatris stands in a very different position than its stock price suggests. The company is extremely undervalued, trading at a forward P/E around 5, offering a solid dividend, and finally showing signs of a sustained recovery. If the transformation continues, with growth in new products, further debt reduction, and a market rerating, the bull scenario price target sits between $16 and $18, reflecting meaningful upside from current levels.

The fair value hinges on robust profit margins, meaningful earnings expansion and a richer future earnings multiple, all compressed into a single, aggressive rerating story. Curious what those projections look like in detail and how they map to that $39.24 figure.

Result: Fair Value of $39.24 (UNDERVALUED)

However, the story could change quickly if earnings growth underperforms those fair value assumptions or if the company’s net income loss persists longer than expected.

Next Steps

Given the mix of optimism and concern running through this story, it makes sense to move quickly. Test the numbers yourself and weigh both sides of the argument with the 3 key rewards and 1 important warning sign

Looking for more investment ideas?

If this Viatris story has sharpened your thinking, do not stop here. Broaden your watchlist with stocks that match clear, disciplined criteria instead of hunches.

• Target potential mispricings by scanning companies that look too cheap relative to their quality using the 50 high quality undervalued stocks
• Strengthen your income stream by checking out stocks with resilient payouts through the 12 dividend fortresses
• Prioritise resilience by focusing on companies that pair solid finances with lower risk profiles via the 1 resilient stocks with low risk scores

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.